Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 204

1.

Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability.

Montironi R, Santoni M, Tartari F, Lopez-Beltran A, Cheng L, Berardi R, Scarpelli M.

Arch Pathol Lab Med. 2016 Jun;140(6):501-2. doi: 10.5858/arpa.2015-0529-LE. No abstract available.

PMID:
27232343
2.

Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.

Schepisi G, Santoni M, Massari F, Gurioli G, Salvi S, Conteduca V, Montironi R, De Giorgi U.

BioDrugs. 2016 May 13. [Epub ahead of print] Review.

PMID:
27177757
3.

Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials.

Berardi R, Santoni M, Rinaldi S, Nunzi E, Smerilli A, Caramanti M, Morgese F, Torniai M, Savini A, Fiordoliva I, Onofri A, Pistelli M, Taccaliti A, Cascinu S.

PLoS One. 2016 May 11;11(5):e0152079. doi: 10.1371/journal.pone.0152079. eCollection 2016.

4.

Updated Management of Malignant Biliary Tract Tumors: An Illustrative Review.

Cannavale A, Santoni M, Gazzetti M, Maher B, Fanelli F, Fiocca F, Catalano C.

J Vasc Interv Radiol. 2016 Apr 20. pii: S1051-0443(16)00203-7. doi: 10.1016/j.jvir.2016.01.149. [Epub ahead of print] Review.

PMID:
27107982
5.

Editorial: Emerging Immunotargets in Genitourinary Tumors.

Montironi R, Santoni M, Massari F, Lopez-Beltran A, Cheng L, Berardi R, Scarpelli M.

Curr Drug Targets. 2016;17(7):748-9. No abstract available.

PMID:
27086839
6.

Hyponatremia in cancer patients: Time for a new approach.

Berardi R, Rinaldi S, Caramanti M, Grohè C, Santoni M, Morgese F, Torniai M, Savini A, Fiordoliva I, Cascinu S.

Crit Rev Oncol Hematol. 2016 Jun;102:15-25. doi: 10.1016/j.critrevonc.2016.03.010. Epub 2016 Mar 10. Review.

PMID:
27066939
7.

Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.

Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Pacifici M, Coppa J, Mazzaferro V, de Braud F, Porta C, Escudier B, Procopio G.

PLoS One. 2016 Apr 11;11(4):e0151662. doi: 10.1371/journal.pone.0151662. eCollection 2016.

8.

Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.

Berardi R, Rinaldi S, Santoni M, Newsom-Davis T, Tiberi M, Morgese F, Caramanti M, Savini A, Ferrini C, Torniai M, Fiordoliva I, Bower M, Cascinu S.

Oncotarget. 2016 Mar 23. doi: 10.18632/oncotarget.8309. [Epub ahead of print]

9.

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.

Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G.

Oncotarget. 2016 Mar 23. doi: 10.18632/oncotarget.8302. [Epub ahead of print]

10.

Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus.

Conteduca V, Santoni M, Medri M, Scarpi E, Burattini L, Lolli C, Rossi L, Savini A, Berardi R, Stanganelli I, Cascinu S, De Giorgi U.

Clin Genitourin Cancer. 2016 Feb 23. pii: S1558-7673(16)30040-4. doi: 10.1016/j.clgc.2016.02.012. [Epub ahead of print]

PMID:
27021585
11.

Prostate cancer: from Gleason scoring to prognostic grade grouping.

Montironi R, Santoni M, Mazzucchelli R, Burattini L, Berardi R, Galosi AB, Cheng L, Lopez-Beltran A, Briganti A, Montorsi F, Scarpelli M.

Expert Rev Anticancer Ther. 2016 Apr;16(4):433-40. doi: 10.1586/14737140.2016.1160780.

PMID:
27008205
12.

Metabolic phenotype of bladder cancer.

Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R.

Cancer Treat Rev. 2016 Apr;45:46-57. doi: 10.1016/j.ctrv.2016.03.005. Epub 2016 Mar 8. Review.

PMID:
26975021
13.

Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4.

Piva F, Santoni M, Scarpelli M, Briganti A, Lopez-Beltran A, Cheng L, Berardi R, Montorsi F, Montironi R.

Eur Urol. 2016 Mar 3. pii: S0302-2838(16)00239-6. doi: 10.1016/j.eururo.2016.02.049. [Epub ahead of print] No abstract available.

PMID:
26947604
14.

Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.

Piva F, Giulietti M, Santoni M, Occhipinti G, Scarpelli M, Lopez-Beltran A, Cheng L, Principato G, Montironi R.

Mol Diagn Ther. 2016 Apr;20(2):111-7. doi: 10.1007/s40291-016-0192-5. Review.

PMID:
26940073
15.

Emerging Immunotargets and Immunotherapies in Prostate Cancer.

Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M.

Curr Drug Targets. 2016;17(7):777-82.

PMID:
26898309
16.

Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?

Modena A, Massari F, Ciccarese C, Brunelli M, Santoni M, Montironi R, Martignoni G, Tortora G.

Target Oncol. 2016 Feb 5. [Epub ahead of print]

PMID:
26846650
17.

Emerging Immunotargets in Bladder Cancer.

Massari F, Ciccarese C, Vau N, Santoni M, Montironi R, Cheng L, Marques RC, Scarpelli M, Fonseca J, Matrana MR, Holger M, Cascinu S, Tortora G, Lopez-Beltran A.

Curr Drug Targets. 2016;17(7):757-70.

PMID:
26844572
18.

AR-V7 and prostate cancer: The watershed for treatment selection?

Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F.

Cancer Treat Rev. 2016 Feb;43:27-35. doi: 10.1016/j.ctrv.2015.12.003. Epub 2015 Dec 18. Review.

PMID:
26827690
19.

Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.

Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullurà D, Santoni M, de Cobelli O, Nolé F.

Crit Rev Oncol Hematol. 2016 Mar;99:324-31. doi: 10.1016/j.critrevonc.2016.01.014. Epub 2016 Jan 19. Review.

PMID:
26818051
20.

Endovascular Repair of Acute and Chronic Aortic Type B Dissections: Main Factors Affecting Aortic Remodeling and Clinical Outcome.

Fanelli F, Cannavale A, O'Sullivan GJ, Gazzetti M, Cirelli C, Lucatelli P, Santoni M, Catalano C.

JACC Cardiovasc Interv. 2016 Jan 25;9(2):183-91. doi: 10.1016/j.jcin.2015.10.027.

PMID:
26793960
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk